Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection

被引:11
作者
Bobbala, Sharan [1 ]
McDowell, Arlene [1 ]
Hook, Sarah [1 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin 9054, New Zealand
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2015年 / 975卷
关键词
Adjuvants; ELSD; Validation; Nanoparticles; Encapsulation efficiency; In vitro release; SALMONELLA-MINNESOTA R595; VACCINE ADJUVANTS; IN-VITRO; STRUCTURAL DETERMINATION; DENDRITIC CELLS; PLGA; FORMULATIONS; DELIVERY; PURIFICATION; LIPOSOMES;
D O I
10.1016/j.jchromb.2014.11.006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Monophosphoryl lipid A (MPL) and Quil A are two immunological adjuvants commonly used in vaccines. At present no simple, validated methods for the quantification of Quil A and MPL have been previously reported therefore the aim of the current study was to develop a simple, fast and validated method to quantify MPL and Quil A using high performance liquid chromatography evaporative light scattering detection (HPLC-ELSD). The HPLC-ELSD technique was carried out using a ZORBAX Eclipse XDB-C8 column (2.1 x 50 mm; particle size, 3.5 mu m) in an isocratic elution mode at 25 degrees C. MPL was eluted at a retention time of 1.8 min with methanol-water as the mobile phase and a detector temperature of 75 degrees C. Quil A was resolved as three peaks with retention times of 4.1, 5.5 and 6.4 mm with a detector temperature of 30 degrees C and with water-acetonitrile and 0.01% formic acid as the mobile phase. The nebulizer pressure and gain were set at 3.5 bar and 10, respectively. Calibration curves plotted for both the adjuvants had an R-2 > 0.997. Accuracy, intra- and inter-day precision were within the accepted limits. The limit of detection for MPL and Quil A were calculated as 1.343 and 2.06 mu g/mL, respectively. The limit of quantification was 2.445 for MPL and 8.97 mu g/mL for Quit A. This analytical method was used to quantify the entrapment and in vitro release of MPL and Quil A in a poly lactic-co-glycolic acid (ALGA) nanoparticle vaccine. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 30 条
  • [1] Analysis of biomass sugars using a novel HPLC method
    Agblevor, F. A.
    Hames, B. R.
    Schell, D.
    Chum, H. L.
    [J]. APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2007, 136 (03) : 309 - 326
  • [2] High performance liquid chromatography with evaporative light scattering detection for the characterisation of a vesicular delivery system during stability studies
    Alsaadi, Manal M.
    Carter, K. Christine
    Mullen, Alexander B.
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2013, 1320 : 80 - 85
  • [3] Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents
    Baldridge, JR
    McGowan, P
    Evans, JT
    Cluff, C
    Mossman, S
    Johnson, D
    Persing, D
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) : 1129 - 1138
  • [4] Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines
    Baldridge, JR
    Crane, RT
    [J]. METHODS, 1999, 19 (01) : 103 - 107
  • [5] PLGA-based nanoparticles: An overview of biomedical applications
    Danhier, Fabienne
    Ansorena, Eduardo
    Silva, Joana M.
    Coco, Regis
    Le Breton, Aude
    Preat, Veronique
    [J]. JOURNAL OF CONTROLLED RELEASE, 2012, 161 (02) : 505 - 522
  • [6] Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes
    Demana, PH
    Fehske, C
    White, K
    Rades, T
    Hook, S
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (05) : 547 - 554
  • [7] Ambiguities in applying traditional Limulus Amebocyte Lysate tests to quantify endotoxin in nanoparticle formulations
    Dobrovolskaia, Marina A.
    Neun, Barry W.
    Clogston, Jeffrey D.
    Ding, Hui
    Ljubimova, Julia
    McNeil, Scott E.
    [J]. NANOMEDICINE, 2010, 5 (04) : 555 - 562
  • [8] Edelman R., 2003, EXPERT REV VACCINES, V2, P167
  • [9] PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release
    Faisant, N
    Siepmann, J
    Benoit, JP
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 15 (04) : 355 - 366
  • [10] Targeting vaccines to dendritic cells
    Foged, C
    Sundblad, A
    Hovgaard, L
    [J]. PHARMACEUTICAL RESEARCH, 2002, 19 (03) : 229 - 238